Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02254772 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Study of Intratumoral Injection of SD-101
A Phase 1 study, sponsored by Robert Lowsky.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT02254772 is a Phase 1 study that has completed, run by Robert Lowsky. The registered enrollment target is 9 participants.
The verdict
NCT02254772, a Phase 1 study, has completed, sponsored by Robert Lowsky.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This phase 1-2 trial studies the side effects and best dose of ipilimumab in combination with toll-like receptor 9 (TLR9) agonist SD-101 and radiation therapy in treating patients with recurrent low-grade B-cell lymphoma.
Interventions
- BIOLOGICAL Ipilimumab
- RADIATION Radiation therapy
- DRUG SD-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2014-09 |
| Est. Completion | 2017-01-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02254772
The ClinicalTrials.gov registry entry for NCT02254772 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Robert Lowsky, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ipilimumab is the first listed.
NCT02254772 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02254772 about?
NCT02254772 is a clinical study titled "A Phase I/II Study of Intratumoral Injection of SD-101". This phase 1-2 trial studies the side effects and best dose of ipilimumab in combination with toll-like receptor 9 (TLR9) agonist SD-101 and radiation therapy in treating patients with recurrent low-grade B-cell lymphoma.
What is the current status of trial NCT02254772?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2014-09. Estimated completion is 2017-01-26.
What interventions are being tested in trial NCT02254772?
The interventions under investigation include: Ipilimumab (BIOLOGICAL), Radiation therapy (RADIATION), SD-101 (DRUG).
Who is sponsoring clinical trial NCT02254772?
This trial is sponsored by Robert Lowsky, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.